![]() |
Name |
violapyrone L
|
Molecular Formula | C11H16O3 | |
IUPAC Name* |
4-hydroxy-3-methyl-6-pentylpyran-2-one
|
|
SMILES |
CCCCCc1cc(O)c(C)c(=O)o1
|
|
InChI |
InChI=1S/C11H16O3/c1-3-4-5-6-9-7-10(12)8(2)11(13)14-9/h7,12H,3-6H2,1-2H3
|
|
InChIKey |
ISVSIKGZEKFBHC-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 196.25 | ALogp: | 2.4 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 50.4 | Aromatic Rings: | 1 |
Heavy Atoms: | 14 | QED Weighted: | 0.752 |
Caco-2 Permeability: | -4.624 | MDCK Permeability: | 0.00002560 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.026 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.171 |
Blood-Brain-Barrier Penetration (BBB): | 0.094 | Plasma Protein Binding (PPB): | 94.84% |
Volume Distribution (VD): | 0.663 | Fu: | 7.92% |
CYP1A2-inhibitor: | 0.82 | CYP1A2-substrate: | 0.942 |
CYP2C19-inhibitor: | 0.256 | CYP2C19-substrate: | 0.701 |
CYP2C9-inhibitor: | 0.425 | CYP2C9-substrate: | 0.924 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.71 |
CYP3A4-inhibitor: | 0.02 | CYP3A4-substrate: | 0.154 |
Clearance (CL): | 4.152 | Half-life (T1/2): | 0.723 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.182 |
Drug-inuced Liver Injury (DILI): | 0.346 | AMES Toxicity: | 0.041 |
Rat Oral Acute Toxicity: | 0.087 | Maximum Recommended Daily Dose: | 0.028 |
Skin Sensitization: | 0.651 | Carcinogencity: | 0.38 |
Eye Corrosion: | 0.45 | Eye Irritation: | 0.928 |
Respiratory Toxicity: | 0.118 |